Thermo Fisher Scientific's Oncomine Dx Target Test Receives FDA Approval as a Companion Diagnostic to Identify Patients Eligible for Newest Targeted Therapy for Non-Small Cell Lung Cancer

Core Insights - Thermo Fisher Scientific has received FDA approval for its Ion Torrent™ Oncomine™ Dx Target Test as a companion diagnostic for identifying patients eligible for treatment with Bayer's new HER2-directed therapy, HYRNUO™ (sevabertinib) [1] Company Summary - The Ion Torrent™ Oncomine™ Dx Target Test is designed to assist clinicians and pathologists in identifying non-small cell lung cancer (NSCLC) tumors [1]